Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02318329
Title Open-Label, Dose-Finding Study Evaluating Safety and PK of FPA144 in Patients With Advanced Solid Tumors
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Five Prime Therapeutics, Inc.
Indications

Advanced Solid Tumor

lymphoma

Therapies

Bemarituzumab

Age Groups: adult
Covered Countries USA


No variant requirements are available.